Simvastatin Trial Underway

The cholesterol-lowering drug Simvastatin is to be trialled as a potential neuroprotective treatment for Parkinson’s. This country-wide trial part-funded by CPT and led by Plymouth University is now underway.Read more

The Grouse & Grape Luncheon 2017

The annual Grouse & Grape Luncheon, held in the beautiful surroundings of Spencer House, raised over £34,000 for The Cure Parkinson's Trust...Read more

The Linked Clinical Trials Meeting 2017

In September 2017, The Cure Parkinson's Trust (CPT) hosted the sixth Linked Clinical Trials conference - an inspiring meeting identifying possible new ways to slow, stop and even reverse Parkinson’s.Read more

Parkinson's and the Beta2-Adrenoreceptor Agonist in Asthma Medication

Researchers have found that compounds in certain drugs used in the treatment of asthma, may also have beneficial effects in Parkinson’s disease.Read more

Rallying to the Challenge 2017 - survey results presented

Leading Parkinson's experts and advocates from around the world gathered at Van Andel Institute in Grand Rapids for a research event highlighting the latest breakthroughs in Parkinson's research and treatments; and the patient focused Rallying to the Challenge symposium with presentation of their recent survey results.Read more

Tom Isaacs Award Recipient Announced

The Cure Parkinson's Trust is delighted to announce the recipient of the inaugural Tom Isaacs Award - Professor Tom FoltynieRead more

Celebrating Tom - an evening of tributes and triumphs.

On 12th September, we celebrated the life and achievements of the wonderful Tom Isaacs - co-founder of The Cure Parkinson's Trust. Tom's incredible legacy remains at the absolute heart of the Trust.Read more

The 'Tom Isaacs Award'

The Van Andel Research Institute and The Cure Parkinson’s Trust will introduce 'The Tom Isaacs Award' to be presented at the annual Grand Challenges in Parkinson’s and Rallying to the Challenge meeting on 27th & 28th September in Grand Rapids, Michigan.Read more

Alpha-synuclein oligomers: a new hope

A report part funded by The Cure Parkinson's Trust assesses the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discusses the advances in our understanding of the role of alpha-synuclein in Parkinson’s and current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.Read more

The Association of Pesticide Use and Parkinson's

Researchers assessed the influence of occupational pesticide use on the prevalence of Parkinson's Disease in people with information available concerning occupational, residential, and household sources of pesticide exposure.Read more

Breaking News: Diabetes Drug Shows Potential as Disease-Modifying Therapy for Parkinson’s

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.Read more

Diabetes drug (Bydureon) Showed Potential as Disease-modifying Therapy for Parkinson's: More Research Needed

At a recent meeting, hosted by The Cure Parkinson's Trust, attendees discussed the impact of the recently published Bydureon trial, related research and the next steps needed for GLP-1 agonists in Parkinson's.Read more

CPT Approves Funding for Two Pre-clinical Studies of Anti-diabetic Drugs

MSDC-0160 and Exendin-4 have shown potential to slow the progression of Parkinson's in pre-clinical work funded by CPT. Moving these drugs to trial is now crucial.Read more

Reducing Inflammation in Parkinson's using a Clinically Approved Cancer Drug

Based on the wealth of evidence that inflammation plays a key role in diseases of the central nervous system, it is thought this line of treatment using a clinically approved cancer drug has significant potential to slow or stop disease progression in Parkinson's.Read more

FDA Approval of Nilotinib in Collaboration Trial

The Cure Parkinson's Trust has collaborated with The Michael J Fox Foundation (MJFF) and the Van Andel Research Institute (VARI) of Grand Rapids, Michigan on the clinical development of nilotinib toward the launch of this clinical trial.Read more

Tribute to Tom

Clare Balding and CPT's own Helen Matthews pay a wonderful tribute to Tom Isaacs on BBC Radio 4, Last Word.Read more

Dogs to be Taught to Sniff Out Parkinson's

Dogs could soon be used to sniff out Parkinson’s disease years before symptoms start to show.Read more

Clinical Data Sharing by People with Parkinson's - paper published

Clinical data sharing and ownership are key issues in modern digital data acquisition. Data sharing is subject to influence by a range of stakeholders. Of these, patient attitudes are pivotal.Read more

Abnormal Protein in Parkinson's Triggers an Immune Response

Researchers have found the first direct evidence that autoimmunity -- in which the immune system attacks the body's own tissues -- plays a role in Parkinson's Disease.Read more

The Cure Parkinson's Trust & Parkinson’s Community Mourn the Loss of Their Champion

“So how has the task of finding better treatments for Parkinson’s made me more passionate, more determined and more fulfilled in my life than I ever thought possible? The answer to this question is simple. It’s the people." - Tom IsaacsRead more